In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe ...

This report details how pleomorphic breast carcinoma evaded initial treatment protocols and spread to 70% of the thorax within months.

Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports ...

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?